胃饥饿素受体激动剂阿那莫林对成骨性肌少症成人肌肉和骨骼的影响
这项随机安慰剂对照1年试验纳入26例50岁及以上成骨性肌少症成人,评估阿那莫林对肌肉和骨骼的作用。阿那莫林未显著改变肌肉量或瘦体重,但使240°/s膝屈曲力矩增加20%(P=.013)、1型前胶原N端前肽(P1NP)增加75%(P=.006)、血清IGF-1增加50%(组间P=.0001),对骨吸收标志物CTX或骨密度无显著影响。
要点
- 阿那莫林未显著改变成骨性肌少症成人的肌肉量或瘦体重。
- 阿那莫林使240°/s膝屈曲力矩增加20%(P=.013),膝伸展变化呈相似但未达统计学显著的效果。
- 阿那莫林使P1NP增加75%(P=.006)、血清IGF-1增加50%(组间P=.0001),对CTX或骨密度无显著影响。
核心结论
- 在这项先导研究中,阿那莫林未显著改变成骨性肌少症成人的肌肉量,但可能改善下肢力量和骨形成,并升高循环IGF-1水平。
- 作者认为值得在该人群中进一步研究阿那莫林。
研究设计与样本
- 随机、安慰剂对照、为期1年的阿那莫林干预试验。
- 研究地点为塔夫茨大学美国农业部营养中心的骨代谢实验室。
- 纳入26名50岁及以上患有成骨性肌少症的男性和女性。
主要发现
- 阿那莫林对肌肉量或瘦体重无显著影响。
- 阿那莫林使240°/s膝屈曲力矩增加20%(P=.013),对膝伸展变化有相似但未达统计学显著的效果。
- 阿那莫林使骨形成标志物P1NP增加75%(P=.006),对骨吸收标志物CTX或骨密度无显著影响。
- 血清IGF-1在阿那莫林组增加50%,在安慰剂组无变化(组间差异P=.0001)。
局限性
- 原文称本研究为先导研究(pilot study)。
- 原文结论指出值得在该人群中进一步研究阿那莫林。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Anamorelin, a ghrelin receptor agonist known to stimulate the pulsatile release of GH from the pituitary, has the potential to improve musculoskeletal health in adults with osteosarcopenia. OBJECTIVE: To determine the effect of anamorelin treatment for 1 year on muscle mass and strength and on biochemical markers of bone turnover in adults with osteosarcopenia (OS). DESIGN: Randomized, placebo-controlled, 1-year anamorelin intervention trial. SETTING: The Bone Metabolism Laboratory at the USDA Nutrition Center at Tufts University. PARTICIPANTS: 26 men and women, age 50 years and older, with OS. MAIN OUTCOME MEASURES: Muscle mass by D3-creatine dilution and lean body mass (LBM) and bone mineral density (BMD) by dual-energy X-ray absorptiometry, muscle strength, serum IGF-1, and bone turnover markers, serum procollagen 1 intact N-terminal (P1NP), and C-terminal telopeptide (CTX). RESULTS: Anamorelin did not have a significant effect on muscle mass or LBM; it significantly increased knee flexion torque at 240°/s by 20% (P = .013) and had a similar nonstatistically significant effect on change in knee extension; it increased bone formation (P1NP) by 75% (P = .006) and had no significant effect on bone resorption (CTX) or BMD. Serum IGF-1 increased by 50% in the anamorelin group and did not change in the placebo group (P = .0001 for group difference). CONCLUSION: In this pilot study, anamorelin did not significantly alter muscle mass; however, it may potentially improve lower extremity strength and bone formation in addition to increasing circulating IGF-1 levels in adults with OS. Further study of anamorelin in this population is warranted.
引用
- Dawson-Hughes B, Barger K, Reitshamer E, et al. Effect of Anamorelin, a Ghrelin Receptor Agonist, on Muscle and Bone in Adults With Osteosarcopenia. J Clin Endocrinol Metab. 2024. PMID: 38057159. doi:10.1210/clinem/dgad702
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。